Our Current and Past Projects
Preclinical Evaluation of Novel Cancer Therapeutics
We have offered extensive bioinformatics assistance and conducted statistical analysis for the preclinical evaluation of numerous innovative nanoscale-based therapies aimed at effectively treating various forms of cancer. Our support includes a wide range of services, such as data analysis, interpretation, and visualization, to ensure accurate and reliable results. By employing advanced computational methods and algorithms, we have been able to analyze complex biological data and identify potential targets for cancer treatment. Our expertise in bioinformatics has played a crucial role in optimizing the development and evaluation process of these novel therapeutics, ultimately leading to more efficient and targeted cancer treatments. Through our collaboration with researchers and scientists, we continue to contribute to the advancement of nanomedicine and the fight against cancer.
References
Pakunlu, R.I., Wang, Y., Tsao, W., Pozharov, V., Cook, T.J. & Minko, T. (2004). Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64(17), 6214-6224.
Saad, M., Garbuzenko, O.B., Ber, E., Chandna, P., Khandare, J.J., Pozharov, V.P. & Minko, T. (2008). Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130(2), 107-114. PMC: PMC3590109.
Taratula, O., Garbuzenko, O.B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V.P., He, H. & Minko, T. (2009). Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 140(3), 284-293. PMC: PMC2787988.
Wang, Y., Saad, M., Pakunlu, R.I., Khandare, J.J., Garbuzenko, O.B., Vetcher, A.A., Soldatenkov, V.A., Pozharov, V.P. & Minko, T. (2008). Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clin Cancer Res 14(11), 3607-3616.
Garbuzenko, O.B., Saad, M., Pozharov, V.P., Reuhl, K.R., Mainelis, G. & Minko, T. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 107(23), 10737-10742. PMC: PMC2890783.
Minko, T., Rodriguez-Rodriguez, L. & Pozharov, V. (2013). Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 65(13-14), 1880-1895.
COVID-19 Treatment
The comprehensive analysis focuses on the various modern therapeutic approaches that have been utilized for the treatment of COVID-19. This analysis includes an in-depth examination of the effectiveness and limitations of these approaches. Furthermore, practical recommendations are provided for the development of novel nanotechnology-based therapeutics. Nanotechnology has emerged as a promising field in the search for effective treatment options for COVID-19. The text explores the potential of nanotechnology in delivering targeted therapies, enhancing drug efficacy, and minimizing side effects. By leveraging the unique properties of nanomaterials, such as their size, surface characteristics, and controlled release capabilities, researchers can design innovative therapeutics that can effectively combat the virus. The recommendations outlined in the analysis aim to provide a roadmap for future research and development in this crucial area.
References
Pozharov, V. P.; Minko, T., Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges. Pharmaceutics 2023, 15 (1). PMC9864317 NIHMS36678823.
Majumder, J.; Minko, T., Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J 2021, 23 (1), 14. PMC7784226 NIHMS33400058.
Treatment of Cystic Fibrosis
Cystic fibrosis, particularly in its lung form known as pulmonary fibrosis, is a highly life-threatening illness. In order to combat this disease, we have been working on the advancement of groundbreaking nanomedicines specifically designed for inhalation treatment of pulmonary fibrosis, as well as other forms of fibrosis. Our aim is to develop innovative therapeutic solutions that can effectively target and treat the various manifestations of fibrosis. By utilizing the potential of nanotechnology in medicine, we hope to revolutionize the treatment options available for patients suffering from this debilitating condition. Together with our dedicated team of researchers and scientists, we are committed to improving the lives of individuals affected by pulmonary fibrosis and other related fibrotic disorders.
References
Ivanova, V., Garbuzenko, O.B., Reuhl, K.R., Reimer, D.C., Pozharov, V.P. & Minko, T. (2013). Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm 84(2), 335-344. PMC: PMC3660419.
Garbuzenko, O.B., Kbah, N., Kuzmov, A., Pogrebnyak, N., Pozharov, V. & Minko, T. (2019). Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release 296: p. 225-231 PMCID: PMC6461390.